The German Chronic Kidney Disease (GCKD) study: design and methods

Eckardt, Kai‐Uwe; Bärthlein, Barbara; Baid-Agrawal, Seema; Beck, Andreas; Busch, Martin; Eitner, Frank; Ekici, Arif B.; Floege, Jürgen; Gefeller, Olaf; Haller, Hermann; Hilge, Robert; Hilgers, Karl F.; Kielstein, Jan T.; Krane, Vera; Köttgen, Anna; Kronenberg, Florian; Oefner, Peter J.; Prokosch, Hans‐Ulrich; Reis, André; Schmid, Matthias; Schaeffner, Elke; Schultheiss, Ulla T.; Seuchter, Susanne A.; Sitter, Thomas; Sommerer, Claudia; Walz, Gerd; Wanner, Christoph; Wolf, Günter; Zeier, Martin; Titze, Stephanie

doi:10.1093/ndt/gfr456

Cited by 141 publications

(162 citation statements)

References 30 publications

Supporting

Mentioning

159

Contrasting

Unclassified

Order By: Relevance

“…The design and methodology of the GCKD study has previously been reported in detail [24,25]. Briefly, the GCKD study is an ongoing prospective observational national cohort study including 5,217 Caucasian patients with CKD of moderate severity from a broad etiologic spectrum.…”

Section: German Chronic Kidney Disease Study (Gckd Study)mentioning

confidence: 99%

Association of relative telomere length with cardiovascular disease in a large chronic kidney disease cohort: The GCKD study

et al. 2015

View full text Add to dashboard Cite

Section: German Chronic Kidney Disease Study (Gckd Study)mentioning

confidence: 99%

Association of relative telomere length with cardiovascular disease in a large chronic kidney disease cohort: The GCKD study

et al. 2015

View full text Add to dashboard Cite

“…1844 subjects had diabetes and in 783 diabetic nephropathy is considered the leading cause of renal failure. The eGFR of diabetic patients in GCKD at baseline was 45 ml/min/1.73m 2 and the urinary albumin/creatinine ratio was 58 mg/g, their HbA1c level averaged 7% and 84% were on RAS blocking agents [10-12]. …”

Section: Discussionmentioning

confidence: 99%

A Prospective Cohort Study in Patients with Type 2 Diabetes Mellitus for Validation of Biomarkers (PROVALID) – Study Design and Baseline Characteristics

Eder

Leierer

Kerschbaum

et al. 2018

Kidney Blood Press Res

View full text Add to dashboard Cite

Background/Aims: The prevalence of diabetes mellitus type 2 and kidney disease in these patients varies widely between European countries. Methods: In addition to store bio-samples the “Prospective cohort study in patients with type 2 diabetes mellitus for validation of biomarkers” collects information on history, physical status, laboratory measurements and medication in 4000 patients with diabetes mellitus type 2, being taken care of at the primary level of healthcare in 5 European countries (Austria, Hungary, Netherlands, Poland and Scotland). Next to comparing the rate of loss of eGFR between the countries, a further objective of the PROVALID study is to determine the 5-year cumulative incidence of renal and cardiovascular outcomes. Results: The mean age of the population recruited is 62.9±10 years, 54.6% are male and the mean BMI is 30.9±5.4 kg/m². Metabolic control (median HBA1c 6.8 % (6.2; 7.5)) is achieved via administration of metformin in 67.4% of the patients and insulin in 30.3%. Median systolic and diastolic blood pressure at recruitment is 135 (125; 146) and 80 (72; 85) mmHg, 65.4% of subjects received RAAS blocking agents. Mean eGFR is 80.7±29.2 ml/min/1.73m² and median baseline albumin/creatinine ratio 8.3 mg (IQR: 3.8 and 25.1). Conclusion: PROVALID will provide information on incidence and progression of renal and cardiovascular disease and therapy in patients with type 2 diabetes mellitus in different European countries. Thus, in contrast to many other cohort studies we will be able to associate national clinical practise pattern with outcome in this highly vulnerable patient population.

show abstract

“…Many SNPs that have been significantly associated with CKD are only nominally associated with ESRD if at all, perhaps suggesting different roles of action or the need for more carefully phenotyped cohorts. Large observational CKD studies such as GEnetics of Nephropathy: an International Effort (GENIE) [49], Chronic Renal Insufficiency Cohort (CRIC) [50] and German Chronic Kidney Disease Study (GCKD) [51] will allow more insight into the development of ESRD, and hopefully lead to the identification of a more comprehensive risk profile for both CKD and ESRD.…”

Section: Discussionmentioning

confidence: 99%

Development of next generation sequencing panel for UMOD and association with kidney disease

Bailie¹,

Kilner²,

Maxwell³

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

Chronic kidney disease (CKD) has a prevalence of approximately 10% in adult populations. CKD can progress to end-stage renal disease (ESRD) and this is usually fatal unless some form of renal replacement therapy (chronic dialysis or renal transplantation) is provided. There is an inherited predisposition to CKD with several genetic risk markers now identified. The UMOD gene has been associated with CKD of varying aetiologies. An AmpliSeq next generation sequencing panel was developed to facilitate comprehensive sequencing of the UMOD gene, covering exonic and regulatory regions. SNPs and CpG sites in the genomic region encompassing UMOD were evaluated for association with CKD in two studies; the UK Wellcome Trust Case-Control 3 Renal Transplant Dysfunction Study (n = 1088) and UK-ROI GENIE GWAS (n = 1726). A technological comparison of two Ion Torrent machines revealed 100% allele call concordance between S5 XL™ and PGM™ machines. One SNP (rs183962941), located in a non-coding region of UMOD, was nominally associated with ESRD (p = 0.008). No association was identified between UMOD variants and estimated glomerular filtration rate. Analysis of methylation data for over 480,000 CpG sites revealed differential methylation patterns within UMOD, the most significant of these was cg03140788 p = 3.7 x 10−10.

show abstract

The German Chronic Kidney Disease (GCKD) study: design and methods

Cited by 141 publications

References 30 publications

Association of relative telomere length with cardiovascular disease in a large chronic kidney disease cohort: The GCKD study

Association of relative telomere length with cardiovascular disease in a large chronic kidney disease cohort: The GCKD study

A Prospective Cohort Study in Patients with Type 2 Diabetes Mellitus for Validation of Biomarkers (PROVALID) – Study Design and Baseline Characteristics

Development of next generation sequencing panel for UMOD and association with kidney disease

Contact Info

Product

Resources

About